Document Detail


Biochemical and functional abnormalities of left and right ventricular function after ultra-endurance exercise.
MedLine Citation:
PMID:  17483127     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There is evidence that ultra-endurance exercise causes myocardial injury. The extent and duration of these changes remains unresolved. Recent reports have speculated that structural adaptations to exercise, particularly of the right ventricle, may predispose to tachyarrhythmias and sudden cardiac death. OBJECTIVE: To quantify the extent and duration of post-exercise cardiac injury with particular attention to right ventricular (RV) dysfunction. METHODS: 27 athletes (20 male, 7 female) were tested 1 week before, immediately after and 1 week after an ultra-endurance triathlon. Tests included cardiac troponin I (cTnI), B-type natriuretic peptide (BNP) and comprehensive echocardiographic assessment. RESULTS: 26 athletes completed the race and testing procedures. Post-race, cTnI was raised in 15 athletes (58%) and the mean value for the entire cohort increased (0.17 vs 0.49 microg/l, p<0.01). BNP rose in every athlete and the mean increased significantly (12.2 vs 42.5 ng/l, p<0.001). Left ventricular ejection fraction (LVEF) was unchanged (60.4% vs 57.5%, p = 0.09), but integrated systolic strain decreased (16.9% vs 15.1%, p<0.01). New regional wall motion abnormalities developed in seven athletes (27%) and LVEF was reduced in this subgroup (57.8% vs 45.9%, p<0.001). RV function was reduced in the entire cohort with decreases in fractional area change (0.47 vs 0.39, p<0.01) and tricuspid annular plane systolic excursion (21.8 vs 19.1 mm, p<0.01). At follow-up, all variables returned to baseline except in one athlete where RV dysfunction persisted. CONCLUSION: Myocardial damage occurs during intense ultra-endurance exercise and, in particular, there is a significant reduction in RV function. Almost all abnormalities resolve within 1 week.
Authors:
A La Gerche; K A Connelly; D J Mooney; A I MacIsaac; D L Prior
Related Documents :
16004927 - Medication and supplement use by athletes.
3341247 - Vitamin and mineral supplementation: effect on the running performance of trained athle...
11237347 - Exercise-induced nausea is exaggerated by eating.
16450167 - Influence of menstrual cycle phase on pulmonary function in asthmatic athletes.
12911417 - Characterization of airway nitric oxide in allergic rhinitis: the effect of intranasal ...
11059467 - The influence of speed, grade and mass during simulated off road bicycling.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-05-04
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  94     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-16     Completed Date:  2008-10-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  860-6     Citation Subset:  AIM; IM    
Affiliation:
Cardiac Investigation Unit, St Vincent's Hospital, PO Box 2900, Fitzroy 3065, Victoria, Australia. Andre.lagerche@svhm.org.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biological Markers / blood
Echocardiography, Doppler, Color / methods
Exercise / physiology*
Female
Humans
Male
Middle Aged
Natriuretic Peptide, Brain / blood
Physical Endurance / physiology*
Troponin I / blood
Ventricular Dysfunction, Left / blood,  etiology,  physiopathology*,  ultrasonography
Ventricular Dysfunction, Right / blood,  etiology,  physiopathology*,  ultrasonography
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Troponin I; 114471-18-0/Natriuretic Peptide, Brain

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of socioeconomic status on survival after primary aortic or mitral valve replacement.
Next Document:  Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.